Method for treating neurological patients having vegetative dysfunction

FIELD: medicine.

SUBSTANCE: method involves estimating vegetative tonus using cardiointervalography approach and its medication adjustment under cardiointervalography control. The cardiointervalography examination is carried out before applying treatment, in the course of and after the treatment. Each time vegetative tonus increment is estimated on the basis of voltage index. When applying medication adjustment, nootrop group preparations are used that are selected before applying treatment with initial vegetative tonus disorder distinguished by vagotonia or sympathicotonia being taken into account. Preparation or combination of preparations or their doses and application duration is adjusted on basis of vegetative status direction changes obtained from cardiointervalography examination data. The treatment is continued until vegetative status direction change stops towards normotonia.

EFFECT: enhanced effectiveness in selecting individual treatment course.

3 cl, 3 dwg

 

The present invention relates to medicine, namely, neurology, and can be used for the treatment of autonomic dysfunction in neurological patients.

Currently, one of the fundamental principles of treatment of autonomic dysfunction in neurological patients is the assessment of autonomic tone (with diagnosis of vagotonia, normotone or sympathotony) with subsequent pharmacological correction of high or low tone (Wayne A. M.,1998, p). For the correction of autonomic tone offers a variety of drugs, particularly drugs of group nootropics, and the prevalence of vagotonia - piracetam, nootropil, acid, entsefabol, cerebral, while the prevalence of sympathicotonia - pikamilon, pantogram, phenibut, GHB (Shabalov, N.P. et al., 2001).

To assess autonomic tone are different known methods, and, primarily, the use of special questionnaires. There are separate questionnaires for the patient and for the doctor, they contain 10-15 questions aimed at identifying discoloration of the skin, the degree of sweating, body temperature, hyperventilation syndrome, deterioration of health with the change of weather, prone to migraines and fainting, disorders of the cardiovascular system, gastrointestinal tract, etc. Positive is whether a negative response to each question of the questionnaire is estimated opredelennim number of points, further according to the total points, the conclusion about the presence or absence of autonomic dysfunction, the degree of objectification can be verified by comparing the data of the patient and the physician (Vegetative disorders. Clinic. Diagnosis. Treatment. Edited Amiina. M., 1998, Chapter 2.1.1).

In order not only to establish the presence or absence of autonomic disorders, and to identify their sympathetic or parasympathetic orientation, there are more detailed tables-questionnaires, in which the number of questions can reach several hundreds. For example, only the skin is analyzed on 10 indicators (color, vascular pattern, oiliness, dryness, dermographism, body temperature and hands, pigmentation, subjective sensation of numbness, humidity and the like). The answer to each question is also being evaluated in points, and then calculates their sum is characteristic of the sympathetic or parasympathetic (Autonomic disorders. Clinic. Diagnosis. Treatment. Edited Amiina. M., 1998, Chapter 2.1.1).

Assessment of autonomic tone with the help of questionnaires and tables is a long, difficult and quite subjective.

At the end of treatment to assess its effectiveness and decide on the need for its continuation or termination also use similar tables questionnaires.

However, the use of tables, questionnaires at this stage along with the same cost (duration, the complexity, subjectivity), suffers from known references to medical treatment: an assessment of not basic, and side effects of drugs, age - or dose-dependent effect.

Thus, treatment of autonomic dysfunction under control assessment of autonomic tone with tables, questionnaires, in some cases, does not give the desired effect. This particularly applies to situations where the assessment of the tone should be carried out urgently, repeatedly over a short period of time, or when contact with the patient because of their age, pathology, language problems impossible.

In addition to tables, questionnaires are used, and such methods of assessing autonomic tone as counting the number of heart rate (HR), the number of breaths (BH), measurement of blood pressure (BP). Although these methods are simple to use, but do not differ in the specificity of indicators at different changes of autonomic tone, dependent on the morphological status of the peripheral organs (heart, lungs, blood vessels), which creates difficulties in assigning adequate, and the more individualized therapy.

The task of the invention is to increase the effectiveness of remedial measures by more adequate selection of treatment nootropics (type of drug, the dosage, duration and frequency of application) through the Denmark features fast, accurate, specific and objective assessment of autonomic tone at various stages of treatment.

The task in the treatment of autonomic dysfunction in neurological patients, including assessment of autonomic tone and medicamental correction it is achieved that the treatment is carried out under control of kardiointervalografii (TG)and TG performed before treatment, mid-treatment and at the end of treatment and each time calculate the index of tension of regulatory systems (INS) and its value assess autonomic tone; medical drug prescribed according to the necessity of harmonizing the autonomic tone in the direction of normotone; in the middle of treatment on the rate of change of the tone according to the CIG spend an adjustment of medication or dose and duration it is used, and the treatment continued until the maximum possible change in autonomic tone in the direction of normotone according to the CIG. JN calculated by the formula:

where

IN the index of tension of regulatory systems,

Mo - fashion - the most common value of R-R interval,

AMO - amplitude fashion - the number of cardiac intervals in percent, corresponding to a range of fashion,

BP - variational span - the difference between the maximum and minimum value of R-R interval.

Assessment Weg the consultative status of the largest IN carried out as follows: when the value IN from 30 to 90 USD judge normotone, when the value < $ 30 - vagotonia, when the value of >90 $ - sympathotony.

Figure 1 shows a graph of the changes of autonomic tone during treatment of the patient with the original simpatotonika (on the stages of selection of therapy, optimal therapy and cessation of therapy).

Figure 2 shows a graph of the changes of autonomic tone during treatment of the patient with the original vagotonic (on the stages of selection of therapy, optimal therapy and cessation of therapy).

Figure 3 shows a graph of the changes of autonomic tone during treatment of the patient with the original simpatotonika and inadequate initial reactions to conventional therapies (at the stages of selection of therapy and optimal therapy).

Treatment under the control of the TG improves the efficiency of the latter by more adequate and individualized selection of treatment the choice of the form of the drug, the dosage and duration of application, and frequency reception due to a more rapid and, if necessary, multiple, independent of age, sex, severity of condition, objective quantitative assessment of autonomic tone at various stages of treatment, i.e. in the selection of a therapy in its adjustment, and at the end of treatment, and to plan further treatment.

It is particularly convenient to use KEY is to adjust the treatment in the middle of this course, since there is a possibility to determine the direction and speed vegetarianismo effect in quantitative data and, if necessary, accelerate or slow down this process accordingly to reduce or extend the time of admission, to predict the optimal duration of therapy.

The adjustment of the form of the drug produced in cases when according to the CIG in the middle of treatment do not achieve persistent vegetarianismo actions or register individual perverted reaction to the applied drug.

Adjustment of dose in the middle of treatment according to the CIG conduct in those cases, when in the middle of treatment is determined by excessive or delayed reaction on the part of the autonomic indicators and perverted response to a standard dose of the drug. In this case, reduce or increase the standard dose of classic drugs or pick up their combinatii.

Because the CIG is very convenient and a short time study at simultaneous high precision control treatment using the CIG creates the possibility of choosing the optimal duration of treatment until then, until there is a termination change of tone towards normotone, i.e. until there is a halting positive effect.

If after completion of the zoom the treatment according to the TG observed deterioration vegetarische status to return to the original state, this can be considered an indication for continued maintenance therapy vegetotherapy drugs.

The proposed method is as follows. Patient before pharmacological treatment is being studied by TG. In the preparatory stage, the patient is placed in a chair high back, where it is within 15 minutes. During this period, fill in the passport part of the future research. To strengthen patient disposable ECG electrodes, respectively II standard abstraction. On the monitor conducts a preview of the initial electrocardiogram with the purpose of the visual assessment. Then performs simultaneous recording and mathematical processing in a computer program 100 cardiocycle the original ECG. At the same time on the screen visually control the quantitative values of Mo (fashion), AMO (amplitude mode), BP (variational sweep), JN (index voltage). IN assess in conventional units (cu) and verbal. JN calculated by the formula:

where

IN the index of tension of regulatory systems,

Mo - fashion - the most common value of R-R interval,

AMO - amplitude fashion - the number of cardiac intervals in percent, corresponding to a range of fashion,

BP - variational span - the difference between the maximum and mini the actual value of R-R interval.

Assessment of autonomic status of the largest IN carried out as follows: when the value IN from 30 to 90 USD in judging normotone, when the value < $ 30 - vagotonia, when the value of >90 $ - sympathotony.

After analysis vegetarisch data hold selection of medicines, determine the form of the drug, its dose, the estimated duration of the treatment. When the source of vagotonia bornim prescribed drugs from the group of piracetam, nootropyl, encephabol, aminalon, cerebral. The majority of patients in this group apply piracetam in the form/m injection 20% p-p of 5.0 by daily course No. 10 or orally in the form of tablets 0.4 rate 1-2 months. Bornim source simpatotonika prescribed drugs from the group of picamilone, pantogama, phenibut, sodium oxybutyrate. Most patients with simpatotonika applied pantogram (0,25-0,5) 1 tablet 2-4 times a day oral course of 1-2 months. If necessary, patients of child, youth or old age, concomitant diseases calculate the age and the individual dose of the drugs. In order to adequately monitor drug therapy this procedure is repeated in the middle of the predictable course of treatment and if necessary (no trend toward normalization of quantitative indicators, the growth of pathological changes or Nali is their perverse reactions) are adjusting treatment by type of drug, the dosage and duration of use, or combine the drugs the same or different groups. The effect of the treatment is controlled using a similar third TG-studies on completion of the course of drug therapy. Every time mathematically handle all of the above indicators and compares them with each other.

Clinical examples

1. The patient Julia M., born in 1988 (history No. 5589), was sterlachini in the neurology Department HZ to the CLINIC with 13.05.02 on 31.05.02 about neurocirculatory dystonia of mixed type with cephalgia, Serebryaniy, sleep disorders on residual organic background perinatal origin, the period of exacerbation. Born from 1 pregnancy occurring with SARS in 10-12 weeks, threat interrupt on 16-week, drug-induced premature delivery at 36-37 week. At birth - prenatal hypotrophy mild. With the birth of hyperactivity, sleep disturbances, frequent belching, concerning which were registered with a neurologist. Often sick with colds. At the age of 6-8 years were vegetative crises of mixed type. Headaches systematically concerned with 7-8 years of age, in high school appeared stable carebastine, sleep disturbance, decreased academic performance.

Objective: the hydrocephalic skull form DG=54 cm, weakly positive but the om Machovina. Muscle tone reduced diffuse, dissociation tendon reflexes along the axis of the body is raised from the hands and lower legs. Asymmetric wasting of the shoulder girdle. Dermographism mixed. Tremor of the eyelids and the tip of the toes. The “game” of pupils. HELL in the dynamics 120/70-120/60 and 100/70-100 / 80g. Tachycardia up to 120-125 in 1 minute

Instrumental study: the fundus of the eye from 15.05.02 - normal. REG from 15.05.02 - vascular dystonia of large and medium caliber of mixed type, a stable tendency to orthostasis. EEG from 14.05.02 - lowering the threshold of convulsive readiness. CT of the brain from 22.05.02 - focal changes are not identified. Echo KG from 14.05.02 - MARS, mitral valve prolapse without regurgitation.

The original CIG before treatment (No. 103) revealed sympathotomy have a tendency to hypersympathicotonia: when in three-dimension, respectively 134,264 - 312,509 - 410,667. The patient is assigned to the b group vitamins (B1 and B6) intramuscularly, ozonated saline intravenously daily for a course of 10 injections, pantogram oral 1 tab. (0,5) 2 times a day. Control holding a CIG in the middle of treatment has registered the following indicators IN: 92,908-88,564-55,059. After a standard course of treatment indicators IN: 76,997-72,665-73,089 that pointed to vegetarianismo the effect of therapy. Along with this marked improvement in overall health, increase efficiency and achievement, reduction and is tensively headaches. Marked clinical and instrumental data allowed us to assess the condition of the patient as offset.

2. The patient, Roman B., born in 1988 (history No. 5745), was sterlachini in the neurology Department HZ to the CLINIC about neurocirculatory dystonia of hypotonic type with cephalgic, zerebrasteniceski syndromes vertigo, dyssomnias on residual organic background perinatal origin, the period of exacerbation. From the anamnesis it is known that born from 1 pregnancy occurring with acute eclampsia, drug-induced birth. At birth, the estimation on Apgar scale 7-8 points. Registered neurologist was not, although the birth was marked by hyperactivity, sleep disorders. I went to school in time, the average performance. Since school began to disturb gradually increasing in intensity headaches, especially after intense mental or physical stress. Later joined fatigue, dizziness, worsened sleep disorders. Objective: the hydrocephalic skull shape, weakly positive symptom Machovina, the asymmetry of the eye slits D<S, bilateral melcorazmashisty nystagmus, increasing the sample de Klein. Easy muscle hypotonia, the tendon entreprise D>s red Dermographism, spilled, hyperhidrosis of the hands and stopmobileredirect the D from 110/60-100/60 to 90/50-90/55. Instrumental data - eyeground in norm (16.05.02), rude signs of intracranial hypertension in the Echo-EG (16.05.02). REG from 15.05.02 - signs of dystonia vessels of medium and large caliber hypotonic type, coarse spasm of the arteries of the third order, venous outflow is obstructed, the tendency to orthostasis in both vascular beds. Echo KG from 15.05.02 - moderate dilatation of the left ventricular cavity. The parameters of contractility on the lower limit of the norm. According to tables-questionnaires - the prevalence of vagotonia.

When carrying out the CIG (No. 112) by a standard method, the following data before treatment: IN at three times the dimension 29,513-23,713-26,735 that regarded as vagotonic mild. In complex therapy applied piracetam intramuscularly 20% aq, 5 ml daily for a course of 10 injections along with b vitamins (B6 and B12), tramparam. In the middle of treatment according to the CIG IN at three times the dimension respectively 42,376-45,441-52,287. The standard treatment is continued until the end of the planned course. At the end of treatment IN at three times the dimension 60,123-63,343-64,988. So marked as clinical as a reduction in headache, dizziness, improve efficiency, and vegetarianismo effects of the treatment, which allowed to assess the condition of the patient as offset.

3. The patient Catherine T., born 13.12.981 (AMB.), complained of mild headache, aggravated by mental stress, when the weather changes, dizziness when changing position of the body, reduced efficiency, sleep disturbance. Sick in the last two years, the disease associates with chronic psychological trauma. There were two conditions that were characterized by shivering, unmotivated fear for the lives of loved ones and their own, throbbing headache, palpitations, shortness of breath, pain in the legs, fever, followed by profuse urination and diarehea.

Objective examination revealed weak convergence, labile photoreceptor reactions, tremor fingertips and age, symmetric recovery of tendon reflexes. Dermographism mixed. Dry skin in combination with hyperhidrosis of the hands and feet. Lability HELL from 130/90-140/90 to 100/70-100/60 and heart rate from 76 to 100 in 1 min

Instrumental examination: REG - from 13.02.03 signs of dystonia vessels large and medium caliber of mixed type, increased peripheral vascular resistance, tendency to orthostasis in the vertebro-basilar system. TV from 17.02.03 - signs of postural disorders, early dysontogenetic osteochondrosis of the thoracic spine, neurocirculatory dystonia. On spondylogenic cervical possono is nick from 14.02.03 - ypravlenie physiological lordosis, instability C2-C3, C3-C4, C4-C5 in flexion and extension.

On the basis of clinical and instrumental data of the patient diagnosed with neurocirculatory dystonia of mixed type with cephalgic, zerebrasteniceski, dissomnic syndromes, vertigo, tendency to vegetative crises mainly sympatho-adrenal type, exacerbation, amid early dysontogenetic osteochondrosis of the spine, postural disorders.

When carrying out the CIG registered the following indicators IN: 238,450-267,857-248,016, which is regarded as sympathotomy. The patient is assigned to outpatient treatment in the form of pantogama oral 1 tab. (0,5) 2 times a day. I/m injection of vitamins B1 and B6. Control TG-study in the mid-course therapy has identified the following indicators TG: 376,344-390,833-327,860, which is regarded as the growth of sympathotony towards hypersympathicotonia. Patient dose was increased pantogama to 1 table. (0,5) 4 times a day, added phenibut 1 tab. (0,25) 2 times a day. On the background skorrigirovanna therapy indicators TG: 107,356-95,187-89,296. Clinically was a decrease in the frequency of headaches, tendency to normalization of sleep, increase efficiency, the cessation of vegetative crises, which is regarded as a state of subcompensation with the recommendation to continue the chosen therapy.

Just use the techniques implemented treatment of 72 patients of both sexes of different ages. Using dynamic kardiointervalografii all patients carried out the monitoring of the treatment process, individualization of treatment and evaluation of the effectiveness of therapy in its various stages.

1. Treatment of autonomic dysfunction in neurological patients, including assessment of autonomic tone with kardiointervalografii (TG) and its medical correction under the control of the TG, wherein the TG is carried out before treatment, during treatment and after treatment, and every time assess changes in autonomic tone on the magnitude of the tension index (ti), and if correct medication use, drugs of group nootropics who choose to treat the disorders of autonomic tone, characterized by vagotonic or sympathicotonia, and in the treatment process for changing the direction of the autonomic tone according to the CIG are adjusting the type of drug or combination drugs or their doses and duration of application with the continuation of treatment until the termination of the changes in autonomic tone in the direction of normotone.

2. The method according to claim 1, characterized in that the evaluation of the autonomic status by the value IN spending following the way: when the value IN from 30 to 90 USD judge normotone, when the value < $ 30 - vagotonia, when the value of >90 $ - sympathotony.

3. The method according to claim 2, characterized in that IN calculated by the formula

where IN the index of tension of regulatory systems,

Mo - fashion - the most common value of R-R interval,

AMO - amplitude fashion - the number of cardiac intervals in percent, corresponding to a range of fashion,

BP - variational span - the difference between the maximum and minimum values of R-R interval.



 

Same patents:

FIELD: pharmaceutical chemistry, in particular pharmaceutical compositions.

SUBSTANCE: new spyro(2H-1-benzopyrane-2,4'-piperidine) derivatives of general formula I

and pharmaceutically acceptable salts thereof are disclosed. In formula dotted line is optional bond; Y is 1-4 substituents independently selected from hydrogen, halogen, C1-C4-alkyl, optionally substituted with one or more halogen, C1-C6-alkyloxy, optionally substituted with halogen or C3-C6-cycloalkyl, C2-C6-alkenyloxy, C2-C6-alkinyloxy, C3-C6-cycloalkyloxy, C6-C12-aryloxy, arylalkyloxy, pyridilmethoxy, SR3, NR3R4, OSO2R5, and NR3SO2R4; or two Y together may form O-(CH2)n-O or O-(CF2)n-O, wherein n is 1 or 2: or Y is condensed C5-C6-aryl group; X is 1-3 substituents independently selected from hydrogen, halogen, hydroxyl, C1-C6-alkoxy, and C1-C4-alkyl; R1 is hydrogen, C1-C4-alkyl, or C6-C12-aryl; R2, R3, and R4 are independently hydrogen or C1-C4-alkyl; R5 is C6-C12-aryl. Also disclosed are pharmaceutical compositions including said derivatives and having activity in relation to CNS.

EFFECT: new compounds with valuable pharmacological action.

9 cl, 1 tbl, 83 ex

FIELD: medicine, obstetrics.

SUBSTANCE: the present innovation deals with three types of species of medicinal plants to prevent late gestoses in pregnant women out of high-risk group: for pregnant women in case of affected dream the suggested species contains flowers of camomile and calendula, leaves of Bergenia and balm, hops collective fruits, and dogrose fruits taken at a certain ratio; for pregnant women in case of chronic urinary infection and neurocirculatory dystonia it contains flowers of camomile and calendula, mountain ash and dogrose fruits, fruits and seeds of Schizandra, leaves of Bergenia and bearberry taken at a certain quantitative ratio; for pregnant women in case of thyroid dysfunction and affected metabolism it contains flowers of camomile and Filipendula, bearberry leaves, Bupleurum grass, fennel seeds, valerian rhizome and roots, hops collective fruits, fruits of black currant taken at a certain quantitative ratio. Species of medicinal plants efficiently prevents and treats at development of both early and late gestoses in pregnant women.

EFFECT: higher efficiency of prophylaxis and therapy.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves administering typical neuroleptics according to titration scheme and tricyclic antidepressants. Neuroleptics are applied according to titration scheme in the morning and tricyclic antidepressants are introduced as intravenous drop-by-drop infusion in the evening in combination with per os application of atypic neuroleptic risperidon. After having given 12-14 intravenous infusions, strategic supporting risperidon psychopharmacotherapy in combination with tricyclic antidepressants during 4-6 months.

EFFECT: enhanced effectiveness in overcoming pharmacological resistance; accelerated schizo-affective syndrome relief.

FIELD: medicine.

SUBSTANCE: method involves administering typical tricyclic antidepressants combined with selective reverse serotonin capture inhibitors. Anxious version of subpsychotic level depressive syndrome of endogenous genesis being treated, intravenous drop-by-drop infusion of 2.-4.0 ml of 1% amitriptiline solution per 200 ml of physiologic saline is applied in 12-14 procedures combined with selective reverse serotonin capture inhibitor given per os, Zoloft is per os administered as the inhibitor at a dose of 50-100 mg. Then, supporting Zoloft therapy is applied at a dose of 100 mg during 3 months. Atypic version of depressive syndrome of subpsychotic level and endogenous genesis is treated with intravenous drop-by-drop infusion of 1.25% Melipramine solution at a dose of 2.0-4.0 ml per 200 ml of power supply source in 12-14 infusions combined with a reverse serotonin capture inhibitor. Paxyl is taken at a peroral dose of 40-60 mg as the inhibitor. Then, supporting Paxyl therapy is applied at a dose of 40-60 mg during 3 months.

EFFECT: enhanced effectiveness of treatment; reduced risk of complications; accelerated depressive syndrome relief.

FIELD: organic chemistry, biochemistry, biology.

SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)

or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.

7 cl, 1 dwg, 2 tbl, 5 ex

FIELD: organic chemistry, biochemistry, biology.

SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)

or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.

7 cl, 1 dwg, 2 tbl, 5 ex

FIELD: organic chemistry, biochemistry, biology.

SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)

or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.

7 cl, 1 dwg, 2 tbl, 5 ex

FIELD: pharmacology.

SUBSTANCE: one should apply glycosaminoglycanes at average molecular weight being 2400 D to prepare pharmaceutical composition for treating senile feeble-mindedness and neurological cerebral lesions induced due to sudden attack or trauma. The innovation suggested increases the number of medicinal preparations of necessary indication.

EFFECT: higher efficiency of application.

7 cl, 2 dwg, 8 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of 1-arenesulfonyl-2-arylpyrrolidine and piperidine of the formula (I):

wherein R1 means hydrogen atom (H), (C1-C7)-alkyl; R2 means furyl, thienyl, pyridyl or phenyl optionally substituted with 1-3 substitutes taken among (C1-C7)-alkyl, (C1-C7)-alkoxy-group, halogen atom, cyano-group, CF3 or -N(R4)2; R3 means naphthyl or phenyl optionally substituted with 1-3 substitutes taken among (C1-C7)-alkyl, (C1-C7)-alkoxy-group, halogen atom, acetyl, cyano-group, hydroxy-(C1-C7)-alkyl, -CH2-morpholine-4-yl, (C1-C7)-alkyloxy-(C1-C7)-alkyl, (C1-C7)-alkyl-N(R4)2 or CF3; R4 means independently of one another hydrogen atom (H), (C1-C7)-alkyl with exception for (RS)-2-phenyl-1-(toluene-4-sulfonyl)pyrrolidine, (RS)-1-(toluene-4-sulfonyl)-2-p-tolylpyrrolidine, N-tosyl-cis-3-methyl-2-phenylpyrrolidine, 3-[1-(toluene-4-sulfonyl)pyrrolidine-2-yl]pyridine and N-tosyl-2-(3,4-dimethoxyphenyl)pyrrolidine, and their pharmaceutically acceptable salts also. Compounds of the formula (I) elicit the effect of agonists or antagonists of metabotropic glutamate receptors that allows their using in pharmaceutical agent useful for treatment or prophylaxis of acute and/or chronic neurological disturbances.

EFFECT: valuable medicinal properties of compounds.

9 cl, 1 tbl, 3 sch, 94 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to nootropic, cerebroprotective medicinal agents as tablets. Tablet of a medicinal agent comprises thiotriazoline and piracetam as active components and accessory components used for formation of core and applying an envelope on it. Invention provides elevating rate and power of a medicinal agent effect on the brain blood supply, expanding spectrum of its pharmacological effect and excludes negative adverse effects.

EFFECT: improved and valuable medicinal properties of agent.

6 tbl

FIELD: medicine, cardiology.

SUBSTANCE: one should register rhythmocardiogram, measure current total power in low-frequency and high-frequency areas of dynamic row of cardiointervals. Evaluation of psychophysiological state should be performed by the value of stress index S calculated due to original mathematical formula by taking into account the power of low-frequency and high-frequency constituents of the range of dynamic row of cardiointervals. In case of standard conditions of measurement - the rest lying at one's back position the value of S stress index should be considered to be equal to 1. The method enables to rapidly and noninvasively detect and range human psychophysiological state.

EFFECT: higher accuracy of evaluation.

2 dwg, 1 ex, 2 tbl

The invention relates to medicine, functional diagnostics and can be used to detect autonomic dysfunction and assessment of adaptive mechanisms of the autonomic nervous system (ANS)

The invention relates to medicine, namely to identify informative parameters of ST-segment electrocardiograma, namely the displacement, slope, shape, deviation of the peak ST-segment from its center, and combinations of these parameters, and can be used to analyze changes in ST-segment electrocardiogram (EX) to detect abnormalities in the early stages of heart disease

The invention relates to medicine, namely to pediatric cardiology

The invention relates to medicine, particularly cardiology

The invention relates to medicine, obstetrics

The invention relates to medicine, obstetrics

The invention relates to medicine, in particular to electrocardiography, and can be used to determine the start of the next cardiac cycle, coinciding with the beginning of P-wave, the analysis of low-amplitude potentials electrocardiogram (EX), temporal parameters EX and analysis of heart rate variability executed as hardware and software

The invention relates to medicine, neurology

FIELD: medicine, cardiology.

SUBSTANCE: one should register rhythmocardiogram, measure current total power in low-frequency and high-frequency areas of dynamic row of cardiointervals. Evaluation of psychophysiological state should be performed by the value of stress index S calculated due to original mathematical formula by taking into account the power of low-frequency and high-frequency constituents of the range of dynamic row of cardiointervals. In case of standard conditions of measurement - the rest lying at one's back position the value of S stress index should be considered to be equal to 1. The method enables to rapidly and noninvasively detect and range human psychophysiological state.

EFFECT: higher accuracy of evaluation.

2 dwg, 1 ex, 2 tbl

Up!